Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Rigel reports positive results from phase II clinical study of R-788

Nov. 15, 2007

Nastech reacquires teriparatide nasal spray for osteoporosis from Procter & Gamble

Nov. 15, 2007

AtheroGenics discontinuing 300 mg dose of AGI-1067 in ANDES trial

Nov. 14, 2007

FDA accepts Akesis' IND application for phase IIa study of AKP-020 for type 2 diabetes

Nov. 14, 2007

Vivus initiates EQUIP phase III trial of Qnexa in morbidly obese patients

Nov. 14, 2007

Phoqus presents update on clinical trial program for Chronocort

Nov. 14, 2007

LY-518674 increases apo A-I production but not HDL cholesterol in metabolic syndrome patients

Nov. 14, 2007

Post hoc analyses of IDEAL, SPARCL studies show additional benefits of atorvastatin

Nov. 14, 2007

Ferric carboxymaltose injection shows promise in non-dialysis-dependent CKD anemia

Nov. 14, 2007

Preliminary study results show FG-4592 well tolerated in CKD anemia

Nov. 14, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...